Orthopediatrics (NASDAQ:KIDS) and Interpace Diagnostics Group (NASDAQ:IDXG) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.
Volatility and Risk
Orthopediatrics has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, Interpace Diagnostics Group has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.
Valuation & Earnings
This table compares Orthopediatrics and Interpace Diagnostics Group’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Orthopediatrics||$72.55 million||11.42||-$13.73 million||($0.87)||-48.72|
|Interpace Diagnostics Group||$24.08 million||0.50||-$26.73 million||($5.58)||-0.54|
Orthopediatrics has higher revenue and earnings than Interpace Diagnostics Group. Orthopediatrics is trading at a lower price-to-earnings ratio than Interpace Diagnostics Group, indicating that it is currently the more affordable of the two stocks.
This table compares Orthopediatrics and Interpace Diagnostics Group’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Interpace Diagnostics Group||-110.80%||-145.12%||-39.55%|
Institutional and Insider Ownership
67.3% of Orthopediatrics shares are owned by institutional investors. Comparatively, 13.6% of Interpace Diagnostics Group shares are owned by institutional investors. 33.6% of Orthopediatrics shares are owned by company insiders. Comparatively, 54.4% of Interpace Diagnostics Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a breakdown of current ratings and price targets for Orthopediatrics and Interpace Diagnostics Group, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Interpace Diagnostics Group||0||0||5||0||3.00|
Orthopediatrics presently has a consensus price target of $53.00, suggesting a potential upside of 25.03%. Interpace Diagnostics Group has a consensus price target of $8.81, suggesting a potential upside of 193.75%. Given Interpace Diagnostics Group’s higher possible upside, analysts clearly believe Interpace Diagnostics Group is more favorable than Orthopediatrics.
Orthopediatrics beats Interpace Diagnostics Group on 9 of the 13 factors compared between the two stocks.
Orthopediatrics Company Profile
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard. It offers trauma and deformity procedures; scoliosis procedures for the treatment of spinal deformity; and sports medicine procedures. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2007 and is headquartered in Warsaw, Indiana.
Interpace Diagnostics Group Company Profile
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.